Kelly Lawrence W & Associates Inc Vertex Pharmaceuticals Inc Transaction History

Kelly Lawrence W & Associates Inc

  • $430 Million
  • Q3 2024

A detailed history of Kelly Lawrence W & Associates Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Kelly Lawrence W & Associates Inc holds 605 shares of VRTX stock, worth $279,334. This represents 0.07% of its overall portfolio holdings.

Number of Shares
605
Previous 1,305 53.64%
Holding current value
$279,334
Previous $611,000 54.01%
% of portfolio
0.07%
Previous 0.14%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$460.0 - $505.78 $322,000 - $354,046
-700 Reduced 53.64%
605 $281,000
Q2 2024

Aug 13, 2024
SELL
$392.81 - $485.53 $60,099 - $74,286
-153 Reduced 10.49%
1,305 $611,000
Q1 2024

May 15, 2024
SELL
$407.69 - $446.08 $4,076 - $4,460
-10 Reduced 0.68%
1,458 $609,000
Q1 2023

May 15, 2023
SELL
$283.23 - $323.1 $39,652 - $45,234
-140 Reduced 8.71%
1,468 $462,000
Q4 2022

Feb 14, 2023
SELL
$285.76 - $321.48 $142,880 - $160,740
-500 Reduced 23.72%
1,608 $464,000
Q1 2022

May 16, 2022
SELL
$221.42 - $260.97 $4,428 - $5,219
-20 Reduced 0.94%
2,108 $550,000
Q1 2021

May 17, 2021
BUY
$207.02 - $241.31 $277,613 - $323,596
1,341 Added 170.39%
2,128 $457,000
Q4 2020

Feb 12, 2021
SELL
$207.01 - $276.09 $365,579 - $487,574
-1,766 Reduced 69.17%
787 $186,000
Q3 2020

Nov 13, 2020
BUY
$255.65 - $303.1 $5,113 - $6,062
20 Added 0.79%
2,553 $695,000
Q2 2020

Aug 14, 2020
SELL
$225.48 - $295.8 $1.17 Million - $1.54 Million
-5,195 Reduced 67.22%
2,533 $735,000
Q1 2020

May 14, 2020
SELL
$199.77 - $247.81 $109,873 - $136,295
-550 Reduced 6.64%
7,728 $1.84 Million
Q4 2019

Feb 14, 2020
SELL
$166.71 - $223.91 $90,856 - $122,030
-545 Reduced 6.18%
8,278 $1.81 Million
Q3 2019

Nov 14, 2019
SELL
$166.23 - $187.09 $35,739 - $40,224
-215 Reduced 2.38%
8,823 $1.5 Million
Q2 2019

Aug 14, 2019
SELL
$164.61 - $190.37 $120,988 - $139,921
-735 Reduced 7.52%
9,038 $1.66 Million
Q1 2019

May 15, 2019
SELL
$163.73 - $194.7 $233,970 - $278,226
-1,429 Reduced 12.76%
9,773 $1.8 Million
Q4 2018

Feb 14, 2019
SELL
$151.91 - $192.21 $18,988 - $24,026
-125 Reduced 1.1%
11,202 $1.86 Million
Q3 2018

Nov 14, 2018
SELL
$167.73 - $192.74 $83,865 - $96,370
-500 Reduced 4.23%
11,327 $2.18 Million
Q2 2018

Aug 14, 2018
SELL
$145.72 - $169.96 $221,494 - $258,339
-1,520 Reduced 11.39%
11,827 $2.01 Million
Q1 2018

May 15, 2018
SELL
$151.6 - $177.13 $1.05 Million - $1.23 Million
-6,955 Reduced 34.26%
13,347 $2.18 Million
Q4 2017

Feb 14, 2018
SELL
$137.28 - $155.55 $55,598 - $62,997
-405 Reduced 1.96%
20,302 $3.04 Million
Q3 2017

Nov 15, 2017
BUY
$148.13 - $162.24 $3.07 Million - $3.36 Million
20,707
20,707 $3.15 Million

Others Institutions Holding VRTX

# of Institutions
1,724
Shares Held
222M
Call Options Held
1.58M
Put Options Held
1.36M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Kelly Lawrence W & Associates Inc Portfolio

Follow Kelly Lawrence W & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kelly Lawrence W & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Kelly Lawrence W & Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email